English
|
中文
HOME
NEWS
EVENTS
Conference
Exhibition
Laws & Regulations
About Us
CAIVD & CPCEM
CAIVD
CPCEM
VIEW
About VIEW
Editorial Board
Contact
Search
News
Home
>
News
Switzerland Global Enterprise Visits CAIVD during CIIE to Foster Sino-Swiss Collaboration in In Vitro Diagnostics
2024-11-15
At the 7th China International Import Expo (CIIE), themed "New Era, Shared Future", representatives from 152 countries, regions, and organizations gathered for national and corporate exhibitions. On 8 November, Switze..
IVD China last week: Roche Diagnostics, Weigao, Hanbon SciTech, BD and JD Health
2025-05-21
Roche Diagnostics Breaks Ground on New Investment Project in Suzhou On May 13, Roche Diagnostics Products (Suzhou) Co., Ltd. (“Roche Diagnostics Suzhou”) held a groundbreaking ceremony f..
China's healthcare sector sees progress in expanding foreign participation
2025-04-22
China's healthcare sector is making steady progress in opening up to foreign investment and expertise, with more than 150 joint-venture and wholly overseas-invested medical institutions now operating nationwide, a senior health official announced Monday.
CACLP 2025 Unveils the Latest Exhibitor List and Global Collaboration and Innovation Highlights Next March
2024-11-14
Taking place 22-24 March at the Hangzhou Grand Convention & Exhibition Center, CACLP 2025—the 22nd China International In Vitro Diagnostic Expo—will make a significant impact, bringing a sharp focus to global in..
Xi arrives in Hanoi for state visit to Vietnam
2025-04-15
Chinese President Xi Jinping arrived in Hanoi on Monday to pay a state visit to Vietnam.
AdvaMed continues pressure on White House to exempt devices from tariffs
2025-04-09
AdvaMed and nine other healthcare organizations have continued to pressure the White House to exempt medical devices and critical supplies from the Trump administration’s ongoing tariff saga.
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
2025-05-23
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.
OncoSwab Announces Collaboration with Mayo Clinic to Advance Non-Invasive Cancer Diagnostics
2025-05-23
OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a collaboration agreement with Mayo Clinic. The agreement provides OncoSwab with access to clinical research expertise and know-how to support the development of its nasal swab-based diagnostic platform.
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase
2025-05-23
Original from: Medtronic Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April ..
Biostate AI Raises $12M in Series A Funding
2025-05-23
Biostate AI said Tuesday that it has raised $12 million in a Series A financing round.
The Annual Report of China IVD Industry 2024 – Chapter 3: Future Trends
2025-05-21
1) Further Popularization of Automated and Intelligent Diagnostic Equipment Currently, most level-Ⅲ hospitals and some level-Ⅱ hospitals in China are equipped with automated and intelligent diagnostic devices...
Biostate AI Raises $12M in Series A Funding
2025-05-21
Biostate AI said Tuesday that it has raised $12 million in a Series A financing round.
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
2025-05-21
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers. Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian cancer (LGSOC) and was the basis of the recent U.S. Food and Drug Administration’s (FDA) accelerated approval of the combination in KRAS-mutated recurrent LGSOC.
Gene Solutions, NEWCL Establish NGS Lab in Taiwan
2025-05-20
Vietnamese genetic testing firm Gene Solutions said Friday that it signed a memorandum of understanding (MoU) with NEWCL Biomedical Laboratory to establish a next-generation sequencing lab in Taiwan.
PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection
2025-05-20
PHASE Scientific International Limited ("PHASE Scientific"), a pioneering biotechnology company revolutionizing early disease detection through proprietary urine-based diagnostics, today announced the successful completion of a US$34 million Series A funding round. This represents the largest Series A raise in Asia’s diagnostic technology sector since 2019, reflecting robust investor conviction in PHASE Scientific’s innovative PHASIFY™ technology and ambitious growth strategy. The funding round is led by a private equity fund managed by Value Partners Group (HKEX: 0806), one of Asia's largest independent asset management firms, with significant backing from new healthcare-focused investors and continued support from existing global backers.
Total:
3258
Pages:
218
First
Prev
1
2
3
4
..
218
Next
End